Biomics Biopharma (ASX:BBM) EV-to-EBITDA: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biomics Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biomics Biopharma's enterprise value is A$0.00 Mil. Biomics Biopharma does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Biomics Biopharma's EV-to-EBITDA at this moment.

The historical rank and industry rank for Biomics Biopharma's EV-to-EBITDA or its related term are showing as below:

ASX:BBM's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 13.065
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-10), Biomics Biopharma's stock price is A$0.00. Biomics Biopharma does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Biomics Biopharma's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Biomics Biopharma  (ASX:BBM) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Biomics Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Biomics Biopharma EV-to-EBITDA Related Terms

Biomics Biopharma EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma EV-to-EBITDA Chart

Biomics Biopharma Annual Data
Trend
EV-to-EBITDA

Biomics Biopharma Semi-Annual Data
EV-to-EBITDA

Biomics Biopharma EV-to-EBITDA Competitor Comparison

For the Biotechnology subindustry, Biomics Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's EV-to-EBITDA falls into.


Biomics Biopharma EV-to-EBITDA Calculation

Biomics Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/
=

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.